Comments to “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”

Ravasio R, Viti R, Roscini SA. Costo per responder di vedolizumab e ustekinumab nel trattamento della malattia di Crohn in pazienti che hanno fallito una precedente terapia con un antagonista del TNF-α in Italia. AboutOpen | 2023; 10: 13-21. https://doi.org/10.33393/ao.2023.2515 DOI: https://doi.org/10.33393/ao.2023.2515

Onali S, Pugliese D, Caprioli FA, et al; IG-IBD. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn’s Disease Patients’ Failure to TNF-Alpha Inhibitors. Am J Gastroenterol. 2022;117(8):1279-1287. https://doi.org/10.14309/ajg.0000000000001773 PMID:35467558 DOI: https://doi.org/10.14309/ajg.0000000000001773

Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51(10):948-957. https://doi.org/10.1111/apt.15706 PMID:32249966 DOI: https://doi.org/10.1111/apt.15706

Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease. Aliment Pharmacol Ther. 2020;52(8):1341-1352. https://doi.org/10.1111/apt.16057 PMID:32955122 DOI: https://doi.org/10.1111/apt.16057

Ibing S, Cho JH, Böttinger EP, Ungaro RC. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis. Clin Gastroenterol Hepatol. 2023 Feb 12:S1542-3565(23)00105. https://doi.org/10.1016/j.cgh.2023.01.038 PMID: 36787837 DOI: https://doi.org/10.1016/j.cgh.2023.01.038

Parrot L, Dong C, Carbonnel F, Meyer A. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2022;55(4):380-388. PMID:34854100 https://doi.org/10.1111/apt.16714 PMID:34854100 DOI: https://doi.org/10.1111/apt.16714

Macaluso FS, Fries W, Privitera AC, et al; Sicilian Network for Inflammatory Bowel Diseases [SN-IBD]. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn’s Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. J Crohn’s Colitis. 2019;13(2):209-217. PMID:30295785 https://doi.org/10.1093/ecco-jcc/jjy156 PMID:30295785 DOI: https://doi.org/10.1093/ecco-jcc/jjy156

Liefferinckx C, Verstockt B, Gils A, et al; Belgian Inflammatory Bowel Disease Research and Development Group [BIRD group]. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study. J Crohn’s Colitis. 2019;13(11):1401-1409. PMID:30989232 https://doi.org/10.1093/ecco-jcc/jjz080 PMID:30989232 DOI: https://doi.org/10.1093/ecco-jcc/jjz080

Iborra M, Beltrán B, Fernández-Clotet A, et al; GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa). Real-world long-term effectiveness of ustekinumab in Crohn’s disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2020;52(6):1017-1030. PMID:32770851 https://doi.org/10.1111/apt.15958 PMID:32770851 DOI: https://doi.org/10.1111/apt.15958

Amiot A, Serrero M, Peyrin-Biroulet L, et al; OBSERV-IBD study group and the GETAID. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310-321. PMID:28593685 https://doi.org/10.1111/apt.14167 PMID:28593685 DOI: https://doi.org/10.1111/apt.14167

Iborra M, Beltrán B, Maroto N, et al. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents. Gastroenterol Hepatol. 2018 Nov;41(9):535-543. https://doi.org/10.1016/j.gastre.2018.11.007 PMID: 30031573 DOI: https://doi.org/10.1016/j.gastre.2018.11.007

Peeters H, Louis E, Baert F, et al. Efficacy of switching to infliximab in patients with Crohn’s disease with loss of response to adalimumab. Acta Gastroenterol Belg. 2018;81(1):15-21. PMID:29562373 PMID:29562373